STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD
Category: #health  By Nikita Chaurasia  Date: 2019-08-23
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD
  • Atrium Spectrum Disorder (ASD) affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity.
     
  • Such technologies are used for the first time in the neurodevelopment field and it is a hugely thrilling project with a scope to change path of this specialty.

STALICLA, a biotech company focused on Autism Spectrum Disorder (ASD) based in Switzerland, reportedly announced the completion of pre-Investigational New Drug (IND) meeting with the United States Food and Drug Administration (FDA) about the preparation for the entry of STP1 into clinical trials.

CEO and Founder of STALICLA, Lynn Durham stated that the company is appreciative of strong interest and technical guidance given by FDA in personalized medicine approaches for Autism Spectrum Disorder (ASD) patients.

Durham added that STALICLA is focused to rapidly move ahead with the submission of STP1 Investigational New Drug (IND). STP1 has the potential to be the first precision medicine for a patient subgroup having Autism Spectrum Disorder and thus herald a new future for this field.

ASD affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity. Eighty percent of patients are considered as idiopathic, with no genetically identifiable cause. Conventionally, drug developers have seen ASD as a single-disease entity, overseeing its biological heterogeneity and clinical complexity.

STP1 is developed by utilizing STALICLA’s systems biology driven platform; DEPI, an integrative framework that utilizes large-scale clinical, pharmacological, molecular and genetic data to define patient subgroups in Autism Spectrum Disorder and to select personalized treatments.

Such technologies are being used for the first time in the neurodevelopment field, and it is a hugely thrilling project with a scope to change path of the specialty.

 

Source Credit: https://venturebeat.com/2019/08/22/stalicla-announces-completion-of-pre-ind-meeting-with-fda-on-stp1-for-subgroup-of-patients-with-autism-spectrum-disorder-asd/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Uber to hire 20,000 drivers in the U.K. as post-lockdown demand surges

Uber to hire 20,000 drivers in the U.K. as post-lockdown demand surges

By Nikita Chaurasia

After lockdown rules eased last month, Uber is reportedly looking to sign up another 20,000 drivers by the end of the year, adding to the 70,000 it already employs in the UK. Uber reported a 50% increase in U.K. trips since April 12, when British re...

Microsoft Teams hits 145 million daily active users amid the pandemic

Microsoft Teams hits 145 million daily active users amid the pandemic

By Nikita Chaurasia

Reportedly, Microsoft Teams currently has 145 million daily active users, demonstrating a 26% increase in user base since October last year when the tech giant had reported 115 million daily active users. The outbreak of the COVID-19 pandemic has fo...

Indian FMCG firms report high demand for sanitizers amidst second wave

Indian FMCG firms report high demand for sanitizers amidst second wave

By Nikita Chaurasia

India’s leading FMCG companies such as ITC Limited, Patanjali Ayurved, and The Himalaya Drug Company have reported high demand for their health and hygiene products recently. The demand for sanitization tools such as hand wash, hand sanitizers...